Dr. Stanley T. Crooke is the founder of Ionis Pharmaceuticals and served as its CEO from 1991 until January 2020. With an M.D. and Ph.D. in medicine, he has dedicated his career to the development of antisense technology, which aims...

Dr. Stanley T. Crooke is the founder of Ionis Pharmaceuticals and served as its CEO from 1991 until January 2020. With an M.D. and Ph.D. in medicine, he has dedicated his career to the development of antisense technology, which aims to improve treatment for various diseases. Under his leadership, Ionis became a leader in RNA-targeted therapeutics, and he holds several key patents in the field. Dr. Crooke's clinical and scientific experience spans nearly 40 years; before founding Ionis, he was the President of Research and Development at SmithKline Beckman Corporation. Known for his strategic insights, he plans to transition to an executive chairman role, remaining active in the company's scientific initiatives. His compensation reflects the high-stakes environment of biotech, with his remuneration reaching nearly $9.5 million in 2020, driven largely by performance-based incentives, aligning his goals with the company's success. Dr. Crooke's background is marked by significant achievements in drug development and his commitment to advancing innovative therapies.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Ionis Pharmaceuticals CEOs

I

Stanley T. Crooke, M.D., Ph.D.

Founder and Ex-CEO of Ionis Pharmaceuticals

Education

M.D., Ph.D.

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1952 - 73 years ago

CEO of Ionis Pharmaceuticals for

29 years 0 months (Jan 1991 - Jan 2020)

Previous Experience

Founder and CEO of Ionis Pharmaceuticals

Rivals

Competitors/colleagues of Stanley T. Crooke, M.D., Ph.D.

Holdings

See how much did Stanley T. Crooke, M.D., Ph.D. make over time.

Stanley Crooke has seen substantial fluctuations in his holdings with Ionis Pharmaceuticals. In early 2019, his holdings peaked at approximately $49.27 million, showcasing significant confidence in the potential of the company’s technology. However, over the following months, his holdings exhibited...

Stanley Crooke has seen substantial fluctuations in his holdings with Ionis Pharmaceuticals. In early 2019, his holdings peaked at approximately $49.27 million, showcasing significant confidence in the potential of the company’s technology. However, over the following months, his holdings exhibited some volatility, dipping to around $39.93 million by April 2020, amid market fluctuations. In late 2020, his holdings surged to a new high of about $98.05 million, coinciding with positive developments in the company’s drug pipeline. This dramatic rise and fall exemplify the nature of biotech investments, where success in clinical trials can lead to substantial increases in stock value, highlighting the risk and reward in the sector. As of now, his holdings reflect a steady portion of his wealth, showing his continuing belief in Ionis's mission.

Mar 11, 2025

I

shares

IONS @ $32.07

Total Stock Sold

$48.77M

IONS

$48.77M

906,058 IONS shares

What if they kept their stock?

If Stanley T. Crooke, M.D., Ph.D. didn't sell their stock, today they would have:
Extra IONS906,058 shares worth $52.89M.
This is 8.45% and $4.12M more than what they got when they sold the stock.

Charitable Transactions

IONS

56,000 shares

IONS

Recent Charitable Transactions

IONS

31,000 shares

IONS

Dec 31, 2020

Charity

IONS

25,000 shares

IONS

Dec 31, 2019

Charity

Insider Trading

See recent insider trades of Stanley T. Crooke, M.D., Ph.D..

IONS

$1.81M

IONS at $63.74/share

Jan 26, 2021

Sale

IONS

$4.60M

IONS at $61.29/share

Jan 21, 2021

Sale

IONS

$2.03M

IONS at $50.14/share

Dec 15, 2020

Sale

IONS

$568.54K

IONS at $51.69/share

Dec 7, 2020

Sale

IONS

$650.15K

IONS at $50.05/share

Nov 25, 2020

Sale

IONS

$739.10K

IONS at $50.31/share

Nov 23, 2020

Sale

IONS

31,000 shares

IONS

Dec 31, 2020

Charity

IONS

$2.62M

IONS at $50.29/share

Sep 21, 2020

Sale

IONS

$886.69K

IONS at $59.45/share

Jun 24, 2020

Sale

IONS

$1.57M

IONS at $58.16/share

Jun 17, 2020

Sale

Compensation History

See how much did Stanley T. Crooke, M.D., Ph.D. make over time.

In 2020, Dr. Stanley T. Crooke received total compensation of approximately $9.49 million, which included a base salary of $683,630, a performance-based bonus of $587,665, and stock options valued at about $4.27 million. His compensation strategy is heavily performance-oriented, reflecting Ionis Pharmaceuticals' success in achieving corporate goals. This aligns the incentives for Dr. Crooke with the long-term interests of shareholders, as the bonus structure is based on various performance metrics like budget achievements and pipeline development. Dr. Crooke's compensation has evolved over the years, reaching a peak of over $9 million recently due to Ionis's strategic position in the biotech market.

Year

2020

Total Compensation

$1.31M

Salary

$683.63K

Board Justification

The compensation philosophy emphasizes performance-based pay, aligning executive compensation with company performance and shareholder interests.

Bonus

$587.67K

Board Justification

Performance-based, at-risk cash compensation based on individual and company performance metrics for 2020.

Other

$39.33K

Board Justification

Includes various benefits such as health insurance and retirement contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2020 as the focus was on cash and options compensation.

Performance Metrics

Performance metrics include achieving budget projections, successful CEO transition, commercial pipeline success, and strengthening the late-stage pipeline.

Other Ionis Pharmaceuticals CEOs

Here are other CEOs of Ionis Pharmaceuticals

Brett P. Monia, Ph.D.

Founder and CEO of Ionis Pharmaceuticals

January 2020 - Present